BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ABBV-547 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of ABBV-547\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07232004-11129@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:ABBV-547: Phase 1 readout est. (NCT07232004)
DESCRIPTION:ABBV-547\, phase 1\, Psoriasis.\nStudy: A Study to Evaluate How
  the Study Drug Moves Through the Body\, Adverse Events\, and How the Body
  Tolerates ABBV-547 Injections\nEstimated primary completion: May 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/abbv-547#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07232004
URL:https://assetmemo.bio/drug/abbv-547#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865105-11129@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:ABBV-547: Phase 2 readout est. (NCT06865105)
DESCRIPTION:ABBV-547\, phase 2.\nStudy: Study of Targeted Therapies for the
  Treatment of Adult Participants With Active Psoriatic Arthritis\nEstimate
 d primary completion: August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/abbv-547#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06865105
URL:https://assetmemo.bio/drug/abbv-547#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
